Dong C, Song Z, Chen J, et al. - Pediatric liver transplant recipients receiving hepatitis B core antibody-positive grafts were examined for the risk factors of developing de novo hepatitis B virus (HBV) infection. Further, the efficacy of the prophylactic strategies in these cases was determined. Researchers followed 139 eligible pediatric recipients for a mean period of 23.5 ± 15.7 months and identified de novo HBV infection incidence of 3.6%. Recipients with de novo HBV infection vs without de novo HBV infection exhibited equal graft and recipient outcome during the follow-up time. Findings support the safety of using hepatitis B core antibody-positive grafts in pediatric liver transplantation under rational prophylactic therapy.